STOCK TITAN
  1. Home
  2. News
  3. LIVN

LivaNova PLC Ordinary Shares - LIVN STOCK NEWS

Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.

LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.

Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.

LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.

The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.

LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.

News

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

Rhea-AI Summary
LivaNova PLC issued a notice to U.S. patients about a cybersecurity incident, exposing personal information. The incident, discovered on November 19, 2023, involved unauthorized access to patient data. The compromised information includes personal details, medical records, and health insurance data. LivaNova took immediate action to address the issue and is offering identity protection services to affected patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
News

LivaNova to Announce First-Quarter 2024 Results

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) will discuss its first-quarter 2024 results in a conference call on May 1, 2024. The live audiocast will be accessible on their website. Listeners can also join via telephone. A replay will be available on the website for 90 days post-call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
earnings
-
News

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) announces positive results from OSPREY clinical study on treating obstructive sleep apnea using targeted hypoglossal nerve stimulation. The study achieved a predictive outcome with over 97.5% probability of meeting primary endpoint, concluding enrollment earlier than expected. The aura6000™ Hypoglossal Nerve Stimulator System showed safety and effectiveness in subjects with moderate to severe OSA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
clinical trial
News

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

Rhea-AI Summary
LivaNova PLC announces the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 in a private offering. The notes will be senior, unsecured obligations bearing interest at 2.50% per year. LivaNova expects approximately $289.3 million in net proceeds, with an option for an additional $45 million. The notes are convertible under certain conditions and may be redeemed at LivaNova's option. The company also plans to repurchase $230.0 million aggregate principal amount of its 3.00% Cash Exchangeable Senior Notes due 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
offering
-
News

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

Rhea-AI Summary
LivaNova PLC announces a private offering of $300 million convertible senior notes due 2029, with additional options for up to $45 million. The notes will be convertible under certain conditions and mature on March 15, 2029. LivaNova may redeem the notes under specific circumstances. The interest rate, conversion rate, and other terms will be determined later. The company expects to enter into capped call transactions to hedge potential dilution and offset cash payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
offering
-
News

LivaNova to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) CEO, Vladimir Makatsaria, to present at Barclays Global Healthcare Conference in Miami. The webcast will be accessible via www.livanova.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
News

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

Rhea-AI Summary
LivaNova PLC reported strong financial results for Q4 and full-year 2023, with revenue growth across all segments. The company initiated a wind down of the Advanced Circulatory Support segment and appointed a new CEO. Revenue for Q4 2023 was $310.1 million, up 12.8% YoY, with U.S. GAAP diluted earnings per share at $0.30. Full-year 2023 revenue was $1.15 billion, up 12.9% YoY, with U.S. GAAP diluted earnings per share at $0.32. The company expects revenue growth of 4-5% for full-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
earnings
-
News

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) announced the appointment of Vladimir A. Makatsaria as the new CEO, effective March 1, 2024. Makatsaria brings extensive experience from Johnson & Johnson MedTech, and the board has expressed confidence in his ability to drive the company's strategic plan and long-term growth. William Kozy will continue as the Board Chair. Makatsaria's 30-year healthcare career includes leadership roles at Johnson & Johnson and a strong track record of innovation and team building.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
News

LivaNova to Wind Down Advanced Circulatory Support Business Unit

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) to Wind Down Advanced Circulatory Support Business, Focus on Core Cardiopulmonary and Neuromodulation Units
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.89%
Tags
none
News

LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) will host a conference call to discuss its Q4 and full-year 2023 results on February 21, 2024. The live audiocast will be accessible at www.livanova.com/events, and a replay will be available on the website for 90 days following the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
earnings

FAQ

What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?

The current stock price of LivaNova PLC Ordinary Shares (LIVN) is $48.985 as of November 4, 2024.

What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?

The market cap of LivaNova PLC Ordinary Shares (LIVN) is approximately 2.9B.

What does LivaNova PLC specialize in?

LivaNova specializes in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies.

Where is LivaNova PLC headquartered?

LivaNova is headquartered in London, UK.

On which stock exchange is LivaNova PLC listed?

LivaNova is listed on the NASDAQ stock exchange under the ticker symbol 'LIVN'.

How many countries does LivaNova operate in?

LivaNova operates in more than 100 countries.

How many employees does LivaNova PLC have?

LivaNova employs approximately 3,000 people worldwide.

What types of products does LivaNova offer?

LivaNova offers products such as surgical heart valves, heart-lung machines, oxygenation equipment, and neuromodulation devices for epilepsy and depression.

What significant mergers have shaped LivaNova?

LivaNova was formed through a merger between Cyberonics in the US and Sorin in Italy.

What percentage of LivaNova's revenue comes from the US market?

Approximately 50% of LivaNova’s revenue is generated from the US market.

What recent changes has LivaNova made to its business focus?

LivaNova has divested its cardiac rhythm management and heart valve businesses to concentrate on its core strengths.

How does LivaNova benefit the healthcare industry?

LivaNova provides innovative medical technologies and therapies that offer both clinical and economic value, benefiting patients, healthcare professionals, and healthcare systems.

Stock LIVN logo
LivaNova PLC Ordinary Shares

Nasdaq:LIVN

LIVN Rankings

#1682 Ranked by Market Cap
N/A Ranked by Dividends

LIVN Stock Data

2.90B
54.15M
0.33%
104.71%
3.82%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
LONDON